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Recombinant adenoviruses (Ad) are among the most extensively used vectors for liver gene
transfer. One of the major limitations for the clinical application of these vectors is the inﬂam-
matory immune response associated with systemic administration of high dose of virus. We
evaluated the effect of Ad administration route on the inﬂammatory immune response and liver
transgene expression. We compared direct intrahepatic injection (IH) with the systemic admin-
istration via tail vein (IV). IH injection of Ad resulted in a lower inﬂammatory response and a
higher transgene expression. When a relatively low dose of virus was used, IV administration
resulted in no detectable protein expression but production of proinﬂammatory cytokines. In
contrast, IH administration induced high levels of transgene expression and no inﬂammation,
althoughwedetected a transient hypertransaminemia,which fully resolvedwithin days. Further-
more, IH injection resulted in a faster protein expression being more intense at the site of
injection, whereas IV administration caused slower but diffuse liver expression. IH injection also
reduced the spreading of the virus to other organs. Independently of the route, depletion of
Kupffer cells signiﬁcantly enhanced the transduction efﬁciency of Ad. This effect was stronger
whenusing IV injection, indicating that IH injectionpartially overcomesKupffer cell phagocytic
activity. Moreover, the antitumor efﬁcacy of high-capacity-Ad encoding murine interleukin-12
(IL-12) was signiﬁcantly greater when the vector was administered by IH injection than when
given IV. In conclusion, IH injection of adenovirus represents a safe and efﬁcient administration
route for clinical applications of gene therapy targeting the liver. (HEPATOLOGY 2006;44:623-632.)
Adenoviral vectors have been shown to efﬁcientlytransfer genetic material to the liver in many ex-perimental models and clinical trials.1-3 First-gen-
eration adenoviruses (Ad) present several advantages over
other gene therapy vectors reviewed in Breyer et al.4 and
Vorburger and Hunt.5 Recently, Ad vectors that are de-
void of all viral coding sequences, called gutless or high-
capacity adenovirus (HC-Ad), have been developed. The
absence of viral genes minimizes the immune response
against the virus, provides large cloning capacity, and en-
ables long-term transgene expression.6,7 Although these
vectors have substantial advantages with respect to ﬁrst-
generation adenoviruses, the production process of
HC-Ad is very laborious, and the virus particles can still
stimulate immune responses, probably as a result of par-
ticle–receptor interaction or internalization.8,9 The major
limitation of adenoviral vectors resides in the strong in-
ﬂammatory reaction generated by the intravascular injec-
tion of a high number of viral particles.10,11 In fact,
infusion of a high dose of second-generation E1/E4 de-
leted adenovirus into the hepatic artery of a patient with
partial ornithine transcarbamylase deﬁciency was fatal be-
cause of a massive inﬂammatory response.12,13 Adenoviral
vectors are predominantly sequestered by the liver within
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minutes after their intravenous administration. A sub-
stantial proportion of the vector dose is captured by
Kupffer cells, and only a fraction of them infect hepato-
cytes, establishing a threshold of the viral dose that should
be administered to obtain detectable amounts of the
transgene product.14-18 Furthermore, on adenovirus up-
take, Kupffer cells get activated and release cytokines,
such as interleukin-6 (IL-6), IL-12, IL-10, IL-8, tumor
necrosis factor alpha (TNF-), interferon gamma (IFN-
), and chemokines such as MIP-1 and MIP-2.19,20
Moreover, viral particles are processed by Kupffer cells
that act as antigen-presenting cells activating helper T
cells and cytotoxic T lymphocytes, which eliminate the
infected cells.21 Therefore, gene therapy procedures using
adenovirus vectors shouldmake use of strategies aiming at
circumventing macrophage phagocytic activity to reduce
toxicity and enhance hepatocyte transduction efﬁciency.
In this work we attempted to improve adenoviral gene
transfer to the liver by simply modifying the route of
vector delivery. Although intravenous (IV) administra-
tion is the simplest way to transduce the liver, other or-
gans such as the spleen, heart, and kidney are also
transduced.22 Intraportal and intra-arterial administra-
tion does not appear to be different from peripheral intra-
venous injection with respect to efﬁciency of hepatic
transduction, systemic vector dissemination, or toxici-
ty.23,24 Biliary infusion is an alternative, but it is techni-
cally difﬁcult and may cause complications.25 Another
route of administration frequently used for adenovirus
administration in cancer gene therapy protocols is the
intratumoral injection. This route has been shown to be
well tolerated and to reduce the spread of the virus.26,27
Our study compares the standard intravenous administra-
tion with direct injection of the virus into liver paren-
chyma (intrahepatic injection, IH) using ﬁrst-generation
adenovirus and high-capacity adenoviral vectors. This ap-
proach has been used for in utero adenoviral administra-
tion but has not been characterized in adult animals.28
Our results indicate that intrahepatic injection of ei-
ther ﬁrst-generation or high-capacity adenoviruses in-
creased liver transgene expression and reduced the
inﬂammatory reaction by circumventing liver macro-
phages. Also we show that the improvement of liver trans-
duction leads to enhanced antitumoral activity of the
vector encoding murine IL-12.
Materials and Methods
Animals. Six- to 8-week-old BALB/c female mice
(Taconic Laboratories, Germantown, NY) were used in
all studies except tumor experiments, in which C57BL/6J
mice were used. Animal handling was performed accord-
ing to regulations of the local animal commission. Bleed-
ing was realized by retroorbital sinus blood extraction,
and serum was collected for subsequent analysis.
Adenovirus Vectors. E1- and E3-deleted adenoviral
vectors carrying human IL-12, luciferase, and -galacto-
sidase cDNA were constructed as previously de-
scribed.27,29 High-capacity or gutless adenovirus vectors
encoding human IL-12 (HC-Ad/RUhIL-12) or murine
IL-12 (HC-Ad/RUmIL-12) were obtained as described.30
Adenoviruses at different doses were administered intra-
venously (through the tail vein in a total volume of 200
L) and intrahepatically, after anesthesia (ketamine),
through direct injection in the left medial lobe (LML) in
a volume of 50 L.
Macrophage Depletion by Clodronate-Loaded Li-
posomes. Liposome-encapsulated clodronate (clodr-
onate-liposomes) and liposomes containing phosphate-
buffered saline (PBS) (control liposomes) were prepared
as previously described.31,32 Dichloromethylene-biphos-
phonate (or clodronate) was a kind gift of Roche Diag-
nostics Gmbh, Mannheim, Germany. Clodronate-
liposomes and PBS-liposomes were administered
intravenously by the tail vein at a dose of 20 L/10 g
animal weight in a total volume of 50 L in saline buffer.
Histological Analysis. Total depletion of liver macro-
phages was conﬁrmed in each experiment by immunoﬂu-
orescence staining using the F4/80 antibody and with a
FITC-labeled goat anti-rat secondary antibody (Pierce
Biotechnology Inc., Rockford, IL). The immunoﬂuores-
cence signal was quantiﬁed by the Aquacosmos software
(Hamamatsu Photonics). X-gal histochemistry was per-
formed on OCT-embedded frozen tissues. Sections were
cut in a cryostat and ﬁxed in 0.5 % glutaraldehyde at
room temperature for 10 minutes. After removal the glu-
taraldehyde the preparations were immersed in X-gal so-
lution and mounted in glycerol.
Determination of Adenovirus Genome Particles in
Different Tissues. DNA was isolated from frozen tissues
using the DNeasy Tissue Kit (Qiagen, Hilden, Germany)
following the manufacturer’s instructions. Adenovirus
DNA was quantiﬁed by means of real-time quantitative
polymerase chain reaction. Primers and TaqMan probe
(Applied Biosystems, Foster City, CA) for Adenovirus E4
gene were designed using the Primer-Express software.
GAPDH was quantiﬁed by real-time quantitative poly-
merase chain reaction as described.33 Results were ex-
pressed as viral genomes (vg) per 106 genome copies of
GAPDH.
Determination of Serum Levels of Aspartate Ami-
notransferase and Alanine Aminotransferase. The
blood level of aspartate aminotransferase (AST) and ala-
nine aminotransferase (ALT) were measured using com-
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mercial kits (Sigma Chemicals, St. Louis MO) in an
Hitachi Automatic Analyzer (Boehringer Mannheim, In-
dianapolis, IN).
Determination of Serum Levels of hIL-12 and Mu-
rine IL-12, IL-6, and IFN-. Sera were assayed at a
1:10 dilution for the hIL-12, mIL-6, and mIFN- and at
a 1:50 dilution for the mIL-12 using OptEIA ELISA Set
kits (Pharmingen, San Diego CA) according to the man-
ufacturer’s protocol.
In Vivo Macroscopic Imaging of Luciferase Activity.
Mice were anesthetized and received a 100-L dose of
D-Luciferin Fireﬂy (Xenogen, Alameda, CA) intraperito-
neally.Mice were placed in a luminometric in vivo system,
a cooled charged coupled device Xenogen IVIS, and data
were analyzed with a Living Image Software (Xenogen).
Areas of 3 cm diameter were quantiﬁed in photons per
second after background subtraction.34
Luciferase Measurement. Tissue sections were fro-
zen in liquid nitrogen until processed. Tissue was homog-
enized in a Luciferase Lysis Reagent (Promega, Madison,
WI). Samples were centrifuged for 15 seconds at 12,000g.
Supernatant was collected and measured in a tube lumi-
nometer. Total proteins were quantiﬁed by Bradford as-
say using bovine serum albumin as a standard.
Tumor Model. Liver metastases were produced by in-
jecting 5  105 MC38 cells in C57BL/6J mice into the
LML after laparotomy in 50 L saline. Survival was
checked daily, and animals were killed if moribund.
Statistical Analysis. All calculations were performed
with SPSS 11.0 software. A normality test (Kolmogorov-
Smirnov) was used to analyze all samples. Normally dis-
tributed samples were analyzed by a paired ANOVA test
for transgene expression experiments. Biodistribution, in-
ﬂammation, and depletion assays were analyzed by a Stu-
dent t test. The data are presented as mean  SD. Non-
normally distributed samples of the cytokine analysis in
the tumor study were analyzed by a Mann-Whitney test
and presented as median (25th, 75th percentile) in the
box-plot. Tumor volume studies were analyzed by a
Kruskal-Wallis test and 2  2 comparisons by a Mann-
Whitney test. Each group of the survival study was ana-
lyzed by the Kaplan-Meier method, and groups were
compared by a log-rank test. P-value was considered sta-
tistically signiﬁcant when P .05 (*) and very signiﬁcant
when P  .01 (**).
Results
Effect of the Route of Adenovirus Administration
on Liver Transduction Efﬁciency. We used a ﬁrst-gen-
eration adenovirus encoding human IL-12 (AdhIL12) to
study the effect of the route of administration on liver
transduction. AdhIL12 was administered to groups of six
BALB/c mice using two different routes, intravenous in-
jection (IV) and intrahepatic injection (IH) and two
doses, 109 and 1010 plaque-forming units (pfu) per
mouse. Serum samples were obtained at days 0 (basal), 1,
2, 3, and 7 after the injection, and hIL-12 was analyzed by
ELISA. As shown in Fig. 1B, transgene expression was
signiﬁcantly higher after IH administration of 1010 pfu, 1
and 2 days after injection than after IV administration
(P  .031 and P  .042 respectively); however, values
were similar from day 3 onward. More importantly, IH
administration of 109 pfu AdhIL-12 (Fig. 1A) resulted in
hIL12 serum levels similar to those obtained after IV in-
jection of a dose 10 times higher (1010 pfu) (1,972.8 
1,309.9 pg/mL vs 2,670.8  2,811 pg/mL), whereas in
mice given 109 pfu AdhIL-12 via IV route no hIL12 was
detected.
To further conﬁrm our observations, we analyzed
the pattern and intensity of expression of a ﬁrst-gener-
ation recombinant adenovirus encoding luciferase (Ad-
luc). BALB/c mice were injected IH and IV with 109
and 1010 pfu/mouse. Luciferase expression was deter-
mined and quantiﬁed at days 1, 3, 7, and 10. As shown
in Fig. 1C-D, signiﬁcant differences on the level of
transgene expression were observed at days 1 and 3
between IH and IV injected animals (P  .001); the
differences disappeared after day 7. As in the case of
AdhIL12, the expression level of 109 pfu of Adluc given
by IH route was similar to the level obtained after IV
injection of a dose 10-fold higher.
We also found differences in the kinetics of transgene
expression depending on the route. Whereas the peak of
IL-12 expression was observed 72 hours after IV admin-
istration, the highest expression level of hIL-12 after IH
injection was detected at 24 hours (Fig. 1B). In the case of
Adluc, transgene expression peaked at 24 hours after virus
injection, whereas after IV injection the peak was at day 7
(Fig. 1C-D).
Next we asked whether IH injection would also im-
prove liver transduction using a high-capacity adenovirus
vector. For this purpose a mifepristone-regulable high-
capacity (gutless) adenovirus encoding hIL12 (HC-Ad/
RUhIL-12) was administered to BALB/c mice (n 6) by
IV or IH injection at a dose of 109 infection units (iu) per
mouse. Two weeks after the administration of the virus,
the inducer, RU486, was administered intraperitoneally
at a dose of 250 g/kg animal weight. Serum was ex-
tracted before RU486 administration and 4, 10, 24, and
48 hours after, and protein expression was analyzed by
ELISA. As shown in Fig. 1E, signiﬁcantly higher levels of
protein expression were observed after IH injection 10
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and 24 hours after the administration of the inducer (P
.034 and P  .038, respectively).
Analysis of Virus Biodistribution. The analysis of
luciferase expression using the charged coupled device
camera showed that the mice that received the vector in-
travenously showed a diffuse expression of the transgene
throughout the whole liver, whereas those animals that
were injected by the IH route showed a local expression at
the site of vector injection (Fig. 2A). To conﬁrm and
supplement in vivo data imaging, animals were sacriﬁced
24 hours after the administration of 1010 pfu Adluc or
AdLacZ, liver was excised, and the LML, right medial
lobe, and right lateral lobe were separated. In both cases
transgene expression was mainly detected at the injected
lobe after IH injection, whereas transgene expression was
similar in the three lobes after IV administration, indicat-
ing that, by this route, the transduction events were dis-
tributed uniformly throughout the liver (Fig. 2B). More
importantly the analysis of luciferase expression in other
organs such as the spleen indicated a lower spreading of
the virus after IH injection (Fig. 2B). To further corrob-
orate these data, the biodistribution of the vector was
analyzed by quantiﬁcation of viral genomes in different
organs 24 hours after adenovirus injection. As shown in
Fig. 2D, IH administration clearly reduces the presence of
adenovirus in lung, heart, and spleen, in comparison with
IV injection. Furthermore, in agreement with the expres-
sion analysis, we observed that after IH injection the
amount of virus is signiﬁcantly higher in the injected lobe.
The Systemic Inﬂammatory Response Generated on
Adenovirus Administration Is Markedly Attenuated
When the Injection Is by IH Route. We analyzed IL-6,
Fig. 1. Improvement of liver transduction by intrahepatic injection of ﬁrst-generation and high-capacity adenovirus. BALB/c mice were injected with
AdhIL12 by intrahepatic (IH) or intravenous (IV) route at a dose of 109 (A) plaque-forming units (pfu) or 1010 (B) pfu/mouse. Human IL-12
concentration in serum was measured. BALB/c mice were injected with Adluc IH or IV at a dose of 109 (C) pfu or 1010 (D) pfu/mouse. Luciferase
expression was analyzed and quantiﬁed. (E) BALB/c mice were injected with 109 infection units (iu)/mouse of HC-Ad/RUhIL-12 by IV or IH injection.
Two weeks after the administration of the virus, mifepristone was administered intraperitoneally at a dose of 250 g/kg. Human IL-12 expression
in serum is presented. All data are presented as a mean of the values obtained from six mice. Error bars represent SD of luciferase and hIL-12
data from six mice. Data from one of two experiments are provided (*P  .05 **P  .01).
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IL-12, and IFN- serum levels in mice 6 and 24 hours
after IH and IV injection of 109 and 1010 pfu Adluc. As
shown in Fig. 3A-C, high levels of IL-6, IL-12, and IFN-
were detected at 6 hours in serum from mice given IV
injection of 1010 pfu Adluc, and increased IL-6 values
were observed in the serum of the animals injected IV
with 109 pfu. Surprisingly, mice receiving an IH dose of
1010 pfu showed very low serum levels of the three cyto-
kines, the values for all of them being undetectable in
mice receiving the low dose of 109 pfu, indicating the
absence of inﬂammatory reaction in those animals.
Liver Injury. To determine vector-mediated hepato-
toxicity, serum samples were analyzed for increases in the
liver enzymes ALT and AST. Because of the biphasic na-
ture of the ALT response to Ad administration,11 the lev-
els of transaminases in serum was assayed at 6 and 24
hours and 7 and 10 days after adenovirus IH or IV injec-
tion. As shown in Fig. 3D-E, at 6 and 24 hours after
injection, all mice that received the virus IV displayed
ALT levels only slightly higher than or within the normal
range. However, in mice injected IH with a viral dose of
109 or 1010, serum transaminases showed a rapid and
marked elevation at 6 hours, whereas no change in
transaminases was detected in mice receiving IH 50 L
saline (data not shown). The rapid upraise of transami-
nases was vector dose dependent and was short-lived, with
a sharp decline 24 hours after vector administration. Dur-
ing the second phase of liver injury at days 7 and 10 after
adenovirus injection, ALT and AST levels were signiﬁ-
cantly higher than in control animals in the groups of
mice receiving 1010 pfu virus independently of the route
of vector injection.
Direct Intrahepatic Administration of Adenovirus
Vector Avoids Kupffer Cell Engulfment. Liver macro-
phages had been shown to engulf a high percentage of
adenoviral particles when they are intravenously inject-
ed.14-18 To test the inﬂuence of macrophages on liver
transduction after IH administration, 24 hours after clo-
dronate-loaded liposomes injection, mice received either
109 pfu Adluc or 109 IU HC-Ad/RUhIL-12. Control
Fig. 2. In vivo and in vitro analysis of luciferase expression after intrahepatic (IH) or intravenous (IV) administration of Adluc and AdLacZ. (A)
BALB/c mice (n  3) were injected with 1010 pfu of Adluc by IH or IV routes. The picture corresponds to the image of luciferase expression 24 hours
after injection and is representative of the results obtained in the rest of mice. (B) Thereafter, mice were killed to isolate the liver and the spleen.
Luciferase expression was measured individually in the three major lobes of the liver: left medial lobe (LML), right medial lobe (injected lobe), and
right lateral lobe and in the spleen by luminometry. Luciferase activity is expressed as RLU per milligram protein. Error bars representSD for triplicate
measurements. (C) BALB/c mice (n  3) were injected with 1010 pfu AdLacZ by IH or IV routes. Mice were sacriﬁced 24 hours after injection, and
-galactosidase expression was analyzed in the three major lobes of the liver. (D) Viral genomes (vg) were quantiﬁed in different organs and tissues:
spleen (S), pancreas (P), lung (Lu), heart (H), brain (B), kidney (K), ovary (O), intestine (I), and muscle (M), 24 hours after IH or IV injection of 1010
pfu of AdLacZ, and normalized by 10-6 GAPDH genome copies. Error bars represent SD for triplicate measurements (*P  .05).
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mice received empty liposomes or saline. Luciferase ex-
pression was analyzed 3 days after vector administration,
and hIL-12 was analyzed 10 hours after the administra-
tion of RU486 at a dose of 250 g/kg. As shown in Fig.
4A-B, and in agreement with previous reports,14-18 a sig-
niﬁcant increase in transgene expression was observed af-
ter macrophage depletion, when mice received IV Adluc
or Ad/RUhIL-12. Injection of empty liposomes also re-
sulted in a marked increase in transgene expression, al-
though not to the same levels. After IH injection of the
vector, transgene expression was also increased by pre-
treatment with empty liposomes; however, the adminis-
tration of clodronate-loaded liposomes did not further
improve transduction. Interestingly, the increment on
transgene expression attributable to macrophage deple-
tion was signiﬁcantly lower after IH than after IV injec-
tion. Analysis of liver sections from mice treated with
empty- or clodronate-loaded liposomes by immunoﬂuo-
rescence (Fig. 4C) using the macrophage marker F4/80
and quantiﬁcation using the Aquacosmos software,
showed that whereas liver macrophages completely disap-
pear after injection of clodronate-loaded liposomes, they
remain intact in the mice that have received empty lipo-
somes or saline.
Intrahepatic Injection of a High-Capacity Adeno-
virus Expressing Liver-Speciﬁc and Regulable Murine
IL-12 Enhances Its Antitumoral Efﬁcacy. To deter-
mine the signiﬁcance of our ﬁndings, we evaluate the
antitumoral effect of a high-capacity adenovirus encoding
murine IL-12 after intrahepatic injection. Thirty
C57BL/6 mice were IH injected with 5  105 MC38
cells. Three days later the mice were opened and tumor
was measured to ensure tumor engraftment and equiva-
lent tumor size in all groups before initiation of the treat-
ment.One group (n 10) received an IV injection of 2
108 IU of an HC-adenovirus expressing mifepristone-in-
ducible murine IL-12 (HC-Ad/RUmIL-12) in 200 L
saline. A second group (n 10) received the same dose of
HC-Ad/RUmIL-12 by IH route in a volume of 50 L,
and the third group received saline by IV (n  5) or IH
(n  5) route. Seven days later, the expression of IL-12
was induced by administration of 250 g RU486 per
kilogram body weight intraperitoneally during 10 consec-
utive days. mIL-12 and mIFN- expression in serum was
measured 10 hours after the ﬁrst and ﬁfth induction by
ELISA. No IL-12 or IFN- were detected in the serum of
animals treated with IH or IV saline. As shown in Fig. 5,
the expression of both cytokines was signiﬁcantly higher
Fig. 3. Intrahepatic injection of adenovirus prevents systemic inﬂammatory reaction induced after intravascular injection. BALB/c mice were
injected with Adluc by IH or IV route at a dose of 109 pfu or 1010 pfu/mouse. Six hours after injection, serum was extracted, and concentrations of
IL-12 (A), IFN- (B), and IL-6 (C) were determined and presented as means of the values obtained from ﬁve mice. (D-E) Six hours and 1, 7, and
10 days after adenovirus injection, serum were extracted from the same mice, and transaminase levels were determined. Data are averages of ﬁve
mice in each group. Error bars represent means  SD. Data from one of two experiments are provided.
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in the group of mice receiving the virus IH. Two of the
mice that received the virus IH died during the period of
induction. These two mice showed the highest levels of
IL-12 and IFN- after the ﬁfth induction. They showed a
rapid weight loss but no liver tumor or pulmonary metas-
tasis, suggesting that the death was caused by IL-12 tox-
icity.
Thirty days after tumor induction, tumor volume was
measured in all mice by laparotomy. Because no differ-
ences were found between the animals receiving saline by
IH or IV administration, they were grouped as control
group. As shown in Fig. 5C, the tumor sizes in the group
of mice that received the vector IH were signiﬁcantly
smaller than in the group that received the vector via tail
vein (P  .038). Furthermore, the survival rate of the
mice was also improved in animals that received the vec-
tor using the IH route compared with IV administration
(P  .02) (Fig. 5D).
Discussion
Adenovirus-based liver-directed gene therapy is fre-
quently performed by injecting the vector intravascularly.
By this route, a high amount of viral particles is needed to
achieve a signiﬁcant level of hepatocyte transduction.
This is a main limitation for clinical application, because
the administration of high doses of adenovirus is associ-
ated with a strong systemic inﬂammatory reaction that
can be very severe and even fatal.11-13 Several strategies
have been tested to reduce adenovirus-mediated inﬂam-
matory reaction without losing transduction efﬁciency.
These include modiﬁcation of vector capsid,35,36 admin-
istration of anti-inﬂammatory or immunosuppression
agents,37,38 and modiﬁcation of the route of administra-
tion.25
When the adenovirus vector is given intravascularly,
the viral particles enter the liver sinusoids, where they
encounter Kupffer cells, which engulf most of the viri-
ons.14 Vector uptake by Kupffer cells has two important
consequences: ﬁrst, it results in a reduction of liver trans-
duction, especially relevant when the vector dose is
low,14,15 and second, Kupffer cells are activated and re-
lease proinﬂammatory cytokines, including IL-6 and IL-
12.19-21 The latter induces the synthesis of IFN-, which
contributes importantly to the toxicity of the vector.20
We obtained higher transduction efﬁciency by IH than
by IV route of Ad administration. Our analysis on the
effect of macrophage depletion on liver transduction after
IH and IV adenovirus injection showed that the injection
of the virus directly into the liver parenchyma partially
overcomes macrophages phagocytic activity. Elimination
of macrophages by using clodronate-loaded liposomes re-
sults in an increase in transgene expression after IH or IV
injection. However, macrophage depletion increased
transgene expression more markedly after IV injection
than after IH administration. By this last route, differ-
ences in the level of transgene expression were not statis-
tically signiﬁcant after macrophage elimination. Of
interest, pretreatment with empty liposomes does not de-
plete Kupffer cells but may temporarily block its phago-
cytic activity increasing transduction of hepatocytes.
Thus, the use of empty liposomes might be an option for
Fig. 4. Intrahepatic (IH) administration partially overcomes macro-
phage phagocytic activity. BALB/c mice were treated IV with saline
solution (saline), PBS-liposomes (liposomes), or clodronate-loaded lipo-
somes (clodronate). Twenty-four hours later, the animals received IV or
IH, 109 pfu of Adluc (A), or 109 iu HD-AdhIL12 (B). (A) Three days after
Adluc injection, luciferase expression was analyzed and quantiﬁed cam-
era and presented as mean of the values obtained from six mice. (B) Two
weeks after HD-AdhIL12 injection, hIL-12 expression was induced by a
single administration of 250 g/kg animal weight of RU486, and blood
samples were collected 10 hours later. The concentration of hIL-12 was
determined and is represented as mean  SD of the values obtained
from three mice. (*P  .05) (C) Mice receiving saline, empty liposomes,
or clodronate-loaded liposomes via tail vein were killed 24 hours later,
and the presence of liver macrophages was analyzed by immunoﬂuores-
cence using an anti-F4/80 antibody. Fluorescence signal was quantiﬁed
and represented as ﬂuorescence intensity per mm2.
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certain clinical applications of liver-directed gene thera-
py.39
Two main consequences result from overcoming mac-
rophage phagocytic activity by injecting the adenoviral
vector directly into the hepatic parenchyma. First, the IH
route leads to a signiﬁcant increase of adenovirus-medi-
ated liver transduction, which is especially important
when a low dose of virus is administered. Second, and very
importantly, IH administration markedly reduces the se-
cretion of proinﬂammatory cytokines in serum. The re-
duction of the systemic inﬂammatory response in
association with augmented transduction efﬁciency is an
advantage of IH leading to increased efﬁcacy with atten-
uated toxicity. Furthermore, the inﬂammatory response
induced shortly after IV administration of adenoviral vec-
tors has been shown to slow transgene expression.40 Thus,
the lower inﬂammatory reaction on IH injection might
explain the earlier peak of transgene expression when us-
ing this route of vector administration.
IH injection resulted in a more restricted distribution
of the vector, which may contribute to lessening the sys-
temic inﬂammatory reaction. Apart from the liver, the
spleen is the organ most affected by adenovirus infec-
tion.10 Our data of luciferase expression and adenovirus
distribution comparing IH and IV injections showed that
the spread of the virus to the spleen and to other organs
such as heart and lung is diminished after IH administra-
tion of the vector. Within the liver, IH injection of Ad
allowed concentration of the expression of transgenic
gene product at the site of injection. This may be advan-
tageous for some clinical applications, as when treating
tumor nodules in which long-term perinodular expres-
sion of IL-12 is desirable.
Adenoviral vectors are associated with a biphasic pro-
ﬁle in liver injury.41 Although the second wave of hepa-
tocellular damage is similar after IH or IV administration,
we observed that hypertransaminasemia occurring few
hours after IH vector injection was dose related and was
Fig. 5. Intrahepatic (IH) administration of HC-Ad/RUmIL-12 results in an enhancement of antitumoral activity. Thirty C57BL/6 mice were injected
IH with 5  105 MC38. Three days later, tumor volume was measured, and mice were separated into three groups of 10 mice according to the
treatment: 2 108 iu HC-Ad/RUmIL-12 IV, 2 108 iu HC-Ad/RUmIL-12 IH, and saline solution IV or IH. After 10 days, IL-12 expression was induced
daily for 10 days by intraperitoneal administration of RU486 (250 g/kg animal weight). Peripheral blood samples were collected 10 hours after
the ﬁrst and ﬁfth induction, and (A) IL-12 and (B) IFN- were analyzed by ELISA. Data are presented in box-plot and were compared using the
Mann-Whitney test. (C) Thirty days after cell injection, tumor volume was measured in all the mice after laparotomy, and values from individual mice
were represented. (D) Kaplan-Meier survival analysis of mice with established MC38 tumors after treatment is assessed (*P  .05; **P  .01 ).
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higher than when using the IV route. Because Ad given by
IH injection may partially escape Kupffer cells, it seems
possible that, when using this route, hypertransaminas-
emia may reﬂect a higher number of virions entering
hepatocytes. This toxicity is rapidly reversible, being over
after 24 hours, and does not affect survival except when
the expressed transgene has an intrinsic toxic effect such as
murine IL-12 in mice.
To determine the signiﬁcance of our ﬁndings, we eval-
uated the antitumoral efﬁcacy of a high-capacity adeno-
virus encoding murine IL-12 given by IH route. In
previous reports, we showed that ﬁrst-generation and
high-capacity adenovirus vectors expressing of murine
IL-12 displayed signiﬁcant antitumor effects in animal
models of liver cancer when given intravenously.13 Our
current work shows that intrahepatic injection of a high-
capacity adenovirus clearly resulted in improved antitu-
mor efﬁcacy. This enhancement of antitumor activity was
associated with a higher production of IL-12 and IFN-
in animals treated by the IH route.
In summary, our data demonstrate that IH injection of
adenoviral vectors reduces adenovirus-mediated systemic
inﬂammatory response and increases transgene expression
by avoiding macrophage uptake. Moreover, we show that
the antitumoral effect of an HC-Ad encoding IL-12 is
boosted when given the vector by IH route. In clinical
practice, intrahepatic injection of Ad can be performed
safely under ultrasound guidance,27 and the IH route
therefore should be considered in the design of gene ther-
apy clinical trials.
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